drugset / Trial / NCT05745623
Study of ICP-723 in Patients With Advanced Solid Tumors or Primary Central Nervous System Tumors
NaSingle-groupOpen-labelTreatment
Summary
A Multi-center, Non-Randomized, Open-Label Phase 2 Basket Clinical Trial to Evaluate ICP-723 in Patients with Advanced Solid Tumors or Primary Central Nervous System Tumors
Timeline
- Start
- 2022-12-27
- Primary completion
- 2027-12-25
- Completion
- 2028-12-25
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | ZURLETRECTINIB | Small molecule | — | Oral |